Skarping, Ida http://orcid.org/0000-0002-1265-8649
Förnvik, Daniel http://orcid.org/0000-0001-5083-7624
Heide-Jørgensen, Uffe
Sartor, Hanna http://orcid.org/0000-0002-1116-5199
Hall, Per http://orcid.org/0000-0002-5640-9126
Zackrisson, Sophia http://orcid.org/0000-0001-5678-3882
Borgquist, Signe http://orcid.org/0000-0001-7938-8893
Funding for this research was provided by:
the Governmental Funding of Clinical Research within National Health Services (ALF), Sweden
Swedish Breast Cancer Group
Lund University
Article History
Received: 24 July 2020
Accepted: 4 December 2020
First Online: 30 December 2020
Compliance with ethical standards
:
: SZ and HS have received speakers’ fees and travel support from Siemens Healthcare AG. SZ has received consultancy fees from Collective Minds Radiology AB. PH is a member of a scientific advisory board for: Cancer Research UK, iCAD and Atossa Genetics. SB has received speakers’ fees from Pfizer, is a member of a Pfizer advisory board, and has received travel support from Roche. The other authors declare they have no competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Regional Ethics Committee in Lund, Sweden (Committee’s Reference Number: 2014/13, 2014/521 and 2016/521).
: Cohort 1: In accordance with the decision from the ethics committee, all living patients received a written letter asking for their consent at the time of the study. Patients declining participation were asked to provide notice to the researchers either by phone or email. Cohort 2: Informed written consent was obtained from all individual participants included in the study.